Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Conatus Pharmaceuticals CNAT

Healthcare Biotechnology
Conatus Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The company is developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease. Emricasan is designed to reduce the activities of human caspases, which are enzymes... see more

Recent & Breaking News (NDAQ:CNAT)

Conatus Announces Completion of Enrollment in ENCORE-PH Phase 2b Clinical Trial of Emricasan in Patients with NASH Cirrhosis and Severe Portal Hypertension

GlobeNewswire April 30, 2018

Benzinga's Biotech Pulse: Takeda Sweetens Shire Offer Again, Menlo's Woes Abound, Earnings Fail to Boost Amgen

Benzinga.com  April 25, 2018

Conatus Pharmaceuticals’ IDN-7314 Pan-caspase Inhibitor Reduces Hepatic Tissue Factor-Driven Coagulation In Vitro and In Vivo

GlobeNewswire April 18, 2018

Conatus Pharmaceuticals Announces Upcoming Oral Presentation at EASL Annual Meeting

GlobeNewswire April 9, 2018

28 Stocks Moving In Thursday's Mid-Day Session

Benzinga.com  April 5, 2018

Mid-Morning Market Update: Markets Open Higher; Monsanto Earnings Miss Expectations

Benzinga.com  April 5, 2018

8 Stocks To Watch For April 5, 2018

Benzinga.com  April 5, 2018

6 Stocks Moving In Wednesday's After-Hours Session

Benzinga.com  April 4, 2018

Conatus Pharmaceuticals Announces Top-line Results from Phase 2b POLT-HCV-SVR Clinical Trial

GlobeNewswire April 4, 2018

Conatus Pharmaceuticals Reports 2017 Financial Results and Program Updates

GlobeNewswire March 7, 2018

Conatus Pharmaceuticals Inc. to Host Earnings Call

Accesswire March 7, 2018

Conatus Pharmaceuticals to Highlight Anticipated Clinical Data Readouts at Upcoming Investor Conferences

GlobeNewswire March 5, 2018

Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results

GlobeNewswire February 28, 2018

Conatus Pharmaceuticals to Highlight Anticipated Clinical Data Readouts and Strategic Initiatives at Upcoming Investor Events

GlobeNewswire February 5, 2018

Conatus to Present at Stifel Healthcare Conference

GlobeNewswire November 7, 2017

Conatus Pharmaceuticals Reports Third Quarter 2017 Financial Results and Program Updates

GlobeNewswire November 1, 2017

Conatus Pharmaceuticals Inc. to Host Earnings Call

Accesswire November 1, 2017

Conatus Pharmaceuticals to Report Third Quarter 2017 Financial Results

GlobeNewswire October 25, 2017

Conatus Pharmaceuticals Announces Poster Presentation at AASLD Annual Meeting

GlobeNewswire October 20, 2017

10 Stocks Moving In Wednesday's After-Hours Session

Benzinga.com  October 18, 2017